FDA Grants Priority Review to Amgen ' s Tarlatamab Application for Advanced Small Cell Lung Cancer
Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC1
If Approved, Tarlatamab Would be the First BiTE® Therapy for a Major Solid Tumor
FDA Target Action Date is June 12, 2024
THOUSAND OAKS, Calif.,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials